Skip to content
Wednesday, 4 November 2026
Inspire.News

Unveiling truth, one story at a time

UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case.

From The Motley Fool 1 min read
Save
UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case.
Image: The Motley Fool

Trial results for its weight loss drugs could justify a higher valuation for the clinical-stage biotech.

Full story

Continue reading this story on The Motley Fool, the publisher that reported it.

Read the full story at The Motley Fool ↗

AI tools

Written by AI from the article text. It can make mistakes; check the original story.

Topics in this story

More from Business

See all